Barclays analyst Matt Miksic raised the firm’s price target on Baxter to $54 from $52 and keeps an Overweight rating on the shares following the “solid” Q4 report. Baxter remains one of the “transformational stories” for 2024, on track to spin its lower-margin, slower-growing renal care business mid-year, the analyst tells investors in a research note. The firm says the company’s Q4 results and achievable 2024 outlook position the stock to outperform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX:
- New Share Price & Shareholder Rights Risk for Baxter International Inc – What’s the Latest?
- Baxter price target raised to $42 from $35 at Deutsche Bank
- Baxter sees FY24 adjusted EPS $2.85-$2,95, consensus $2.93
- Baxter sees Q1 adjusted EPS 59c-62c, consensus 62c
- Baxter reports Q4 adjusted EPS 88c, consensus 86c